Historical profile. In a report published in 1999, Cambridge doctors described a 9-year-old girl who weighed 94.4 kilograms, about 208 pounds. She had a rare condition called congenital leptin deficiency: a genetic mutation meant her body could not produce leptin, the hormone fat tissue uses to communicate information about stored energy to the brain.
The girl was constantly hungry. She sought food between meals and struggled to feel satisfied after eating. The problem was not simply a matter of appetite or self-control. Her body was missing a biological signal essential to regulating hunger.
Within seven days of starting daily leptin injections, her food-seeking behavior had changed markedly. Within two weeks, she began losing weight. A year later, she had lost 16.4 kilograms, almost all of it fat.
The first author of the New England Journal of Medicine report describing her treatment was a young clinician named Sadaf Farooqi. Working with Stephen O’Rahilly and other Cambridge researchers, she helped establish something that would reshape obesity science: in some people, overwhelming hunger is the consequence of a specific biological defect, and correcting that defect can change eating behavior dramatically.
The case was extraordinary because it was rare. Most people with obesity are not deficient in leptin, and giving them more does not produce the same response. But the experiment opened a window into the circuits that regulate human appetite.
Farooqi has spent the decades since following that window into the genetics of hunger.
A Hormone That Worked in Mice, and a Question About Humans
The modern leptin story began in 1994, when researchers identified the gene responsible for obesity in a strain of laboratory mice. The animals could not produce a functioning hormone that normally helps the brain monitor the body’s energy reserves.
Without that signal, the mice became excessively hungry and developed severe obesity. Giving them leptin reversed much of the problem.
The discovery raised an obvious question. Could leptin work as a treatment for obesity in humans?
The answer proved more complicated. Most people with obesity already have relatively high concentrations of leptin because the hormone is made by fat tissue. Their bodies produce the signal, but the appetite-regulating system does not respond to it in the same way as someone with a complete hormone deficiency.
That made leptin disappointing as a broad weight-loss treatment. But the Cambridge research group led by Stephen O’Rahilly, with Farooqi as a key collaborator, pursued a narrower question: what happens in the rare people whose leptin system is genetically broken?
In June 1997, a paper in Nature, with Carl Montague and Farooqi as joint first authors, described children with severe, early-onset obesity caused by mutations in the gene responsible for producing leptin.
The affected children were not simply making too little hormone because of lifestyle, diet or body size. They had inherited a defect that prevented normal leptin production.
According to the University of Cambridge’s research impact record, the group also helped identify another single-gene cause of severe obesity involving prohormone convertase 1, an enzyme needed to process certain hormone precursors.
These discoveries began to establish that some forms of severe childhood obesity could be traced to individual genetic defects rather than explained solely by behavior or environment.
The next question was whether replacing the missing leptin could change a patient’s life.
For most people with obesity, leptin was not the missing ingredient. For a handful of children, it was exactly that.
What One Patient With Leptin Deficiency Showed
The clinical report published on September 16, 1999, described treatment of the older of two cousins previously identified with congenital leptin deficiency.
The girl had begun gaining excessive weight at approximately four months of age. By nine, she weighed 94.4 kilograms. Her condition had already contributed to serious mobility problems, and she had undergone procedures intended to improve them.
The paper described her family as being of Pakistani origin and reported that her parents were first cousins, a relevant detail because the disorder was caused by an inherited recessive genetic mutation.
The Cambridge team treated her with recombinant human leptin, given by daily subcutaneous injection for 12 months. The dose was designed to reach only about one-tenth of the leptin concentration predicted for someone of her age, sex and body composition.
Even that relatively small replacement dose had a striking effect.
The researchers reported that within seven days, her mother and an investigating physician observed a substantial change in eating behavior. She began eating amounts similar to those consumed by her siblings and was no longer persistently seeking food between meals.
At a standardized test meal, her energy intake fell from approximately 1,600 calories before treatment to 930 calories afterward, a reduction of 42 percent.
She started losing weight within two weeks. After 12 months, she was 16.4 kilograms lighter.
Body-composition measurements showed that 15.6 kilograms of the loss came from fat, accounting for approximately 95 percent of the total. Her body-fat percentage fell from 59 percent to 52 percent.
The treatment did not work by making her body burn vastly more energy. Her basal metabolic rate declined as she lost weight, while changes in physical activity helped offset that reduction. The researchers concluded that leptin’s principal effect on her weight came through suppressing food intake.
The lesson was not that a hormone melted fat. It was that replacing a missing signal made relentless hunger subside.
There were qualifications. This was one child, observed without a control group. It established a powerful proof of principle for treating congenital leptin deficiency, not a therapy for obesity in general.
She also developed antibodies against the injected leptin after approximately two months. The researchers described them as non-neutralizing, and they did not appear to interfere with the treatment response, although they complicated laboratory measurements.
Hormone measurements suggested the early stages of puberty might be developing, another important finding because congenital leptin deficiency can disrupt reproductive development. But the investigators acknowledged that a single case could not settle exactly how leptin influences the timing of puberty.
Still, something fundamental had been demonstrated in a human patient: appetite could be powerfully influenced by a biological signal whose absence was determined by genetics.
From One Gene to the Brain’s Appetite Circuit
Farooqi’s larger contribution has been following the implications of that early work across many more patients.
Through the Genetics of Obesity Study, known as GOOS, she and colleagues including O’Rahilly recruited people with severe, early-onset obesity to investigate the molecular mechanisms behind unusually strong appetites and weight gain.
A historical University of Cambridge research impact case study documented a cohort of more than 4,000 patients. The researchers used genetic analysis to identify mutations affecting several components of the body’s appetite-regulating machinery.
One of the most important findings involved the melanocortin 4 receptor, or MC4R, a receptor in the brain that helps regulate food intake and energy balance.
Leptin is part of an interconnected signaling system. Its actions influence neural pathways involving other molecules, including pro-opiomelanocortin, or POMC, and downstream melanocortin receptors.
When a crucial component of that system is impaired by a pathogenic genetic variant, appetite regulation can be seriously disrupted.
Cambridge researchers found that loss-of-function mutations in MC4R were present in approximately 5 to 6 percent of children with severe obesity in studied populations, making MC4R deficiency one of the more common identifiable single-gene causes of severe obesity.
That percentage should not be confused with the prevalence of MC4R mutations among everyone who has obesity. The genetic study populations were selected for unusually severe disease, often beginning early in childhood.
According to the Cambridge impact record, by 2006 MC4R sequencing had become part of the diagnostic evaluation of some children with severe obesity.
Research also identified the importance of defects involving the leptin receptor, POMC, BDNF and other components of the neural systems controlling appetite.
The discoveries helped shift the question from whether a person was eating too much to why their brain was generating such a powerful drive to eat.
That approach eventually connected genetic diagnosis to precision treatment.
One example is setmelanotide, a peptide medicine that activates MC4R. Developed by Rhythm Pharmaceuticals, it became a treatment for certain rare forms of genetically determined obesity.
The U.S. FDA first approved setmelanotide, marketed as Imcivree, in November 2020 for chronic weight management in patients with obesity caused by particular POMC, PCSK1 or leptin-receptor deficiencies. The drug’s approved indications subsequently expanded, including to Bardet-Biedl syndrome.
It is not a treatment for every MC4R mutation, nor was it approved for common polygenic obesity. The regulatory distinction matters because activating a receptor only works when the biological pathway remains sufficiently functional to respond.
For a small group of patients, however, the genetics of their obesity can now help determine which medicine may work.
One child’s missing hormone helped open a map of the brain circuits that regulate hunger. That map eventually pointed toward new drugs.
The Argument Sadaf Farooqi Keeps Making
There is a public implication to Farooqi’s work that extends well beyond the people with rare genetic disorders.
At the American Diabetes Association’s 2019 Scientific Sessions, Farooqi argued that eating behavior is not entirely a matter of free choice. She emphasized the biological mechanisms built into the brain while acknowledging that environmental factors also shape weight and food intake.
The distinction is important. A person’s actions still matter, and environment can influence whether genetic susceptibility translates into weight gain. But hunger itself is not simply a moral decision, and people can experience very different biological drives to eat.
The 1999 leptin patient gave the researchers an unusually clear demonstration of that distinction. Restoring a deficient hormone changed the child’s eating behavior rapidly, without relying on a new diet plan or an appeal to greater willpower.
Farooqi’s team has also studied the other end of the weight spectrum: people who remain unusually lean.
Some genetic variants reduce appetite and protect against weight gain. Others have the opposite effect. Studying both groups can reveal how the same signaling systems contribute to differences in body weight across the population.
Recognition of that work has continued.
In March 2026, the European Association for the Study of Obesity and the Novo Nordisk Foundation awarded Farooqi the Obesity Prize for Excellence for her contributions to understanding the biological mechanisms behind obesity.
The award package totaled DKK 2 million, including DKK 300,000 as a personal prize and DKK 1.7 million to support further research.
The Endocrine Society also selected her for its 2026 Gerald D. Aurbach Award for Outstanding Translational Research, recognizing work that connects fundamental discoveries to patient care.
The Novo Nordisk Foundation’s involvement in the obesity prize is relevant context given Novo Nordisk’s position in the commercial obesity-drug market. The award recognizes scientific achievement, but transparency about the organizations funding major honors remains appropriate in a field with enormous financial stakes.
The larger achievement is not simply a collection of prizes. It is the development of an approach to obesity research in which a patient’s unusually strong hunger is treated as a biological phenomenon worth investigating, rather than dismissed as a failure of discipline.
Why Sadaf Farooqi’s Work Matters in the GLP-1 Era
Modern obesity medicine has moved into a different commercial era.
Semaglutide, tirzepatide and newer experimental multi-receptor medicines produce weight loss through effects on appetite, food intake and metabolic regulation. Their mechanisms differ from leptin replacement, and they do not simply duplicate the leptin-MC4R pathway.
But they belong to a wider scientific picture in which the brain responds to hormonal information about nutritional state, energy availability and food consumption.
The idea that hormones can alter the drive to eat was fundamental to Farooqi’s early research. It is now central to how obesity medicines are developed, evaluated and discussed.
Readers of Grey Pepper’s profile of Masayasu Kojima and the discovery of ghrelin will recognize another part of the same story. Ghrelin, largely produced in the stomach, is one of the hormonal signals involved in stimulating hunger.
Our coverage of leptin signaling, microglia and APOE4 in experimental mouse research explores how complex those brain-related signaling systems can become.
The important connection is conceptual, not that all these hormones work through an identical receptor or biological mechanism.
Hunger is regulated by overlapping signals that influence the brain. Disrupting one component can sometimes produce severe changes in appetite, while modifying other components can help treat obesity.
Still, rare single-gene disorders explain only a minority of obesity cases.
Most people who develop obesity do not carry a single mutation that can be identified and corrected with one replacement hormone. Their body weight reflects the combined effects of many genetic variants, biological mechanisms, environmental exposures and behaviors.
Farooqi made that limitation clear in 2019 when discussing the GOOS cohort. Even among patients selected for severe obesity, MC4R-related genetic findings accounted for only part of the picture.
The existence of a powerful biological explanation does not automatically identify the right treatment for every patient. Nor does it mean environmental factors are irrelevant.
That is the unresolved challenge in obesity medicine: moving from an increasingly detailed map of appetite-regulating biology to treatments tailored to the different reasons people gain weight.
One Patient, and a Different Way of Thinking About Hunger
There are important limits to what the original leptin case proves.
It was not a randomized trial. It involved one child with an exceptionally rare disorder. The dramatic results cannot be generalized to ordinary obesity, and the study did not establish a universal solution for appetite control.
But the strength of the case came from the clarity of its biological explanation.
The researchers had identified a genetic mutation. They understood the hormone that was missing. They replaced that hormone, observed a rapid change in eating behavior and documented sustained weight loss over a year.
That sequence helped turn an abstract theory about appetite into something visible in a patient.
In the decades that followed, Farooqi and her collaborators extended the work into the genetics of obesity, the leptin-melanocortin pathway, clinical diagnosis and targeted treatment.
The science has become far more complicated than one hormone and one patient. But the original observation retains its power.
A 9-year-old girl was living with relentless hunger because her body could not produce a necessary signal. Within a week of replacing it, her eating behavior changed.
That was not a lesson in willpower. It was a lesson in biology.
And it helped change how medicine understands the people who are hungry.
Sources
- Farooqi IS, Jebb SA, Langmack G, et al. Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency. New England Journal of Medicine. September 16, 1999. DOI: 10.1056/NEJM199909163411204.
- Montague CT, Farooqi IS, Whitehead JP, et al. Congenital Leptin Deficiency Is Associated with Severe Early-Onset Obesity in Humans. Nature. June 26, 1997. DOI: 10.1038/43185.
- University of Cambridge / Research Excellence Framework. Genetic Diagnosis and Therapeutic Intervention in Patients with Severe Early-Onset Obesity. Historical research impact case study.
- American Diabetes Association Meeting News. Outstanding Scientific Achievement Award Lecturer: Genetics Play a Key Role in Obesity, Thinness. June 11, 2019.
- European Association for the Study of Obesity. Obesity Prize for Excellence Awarded to Clinical Researcher for Distinguished and Innovative Work in Obesity and Its Complications. March 19, 2026.
- Endocrine Society. Endocrine Society Honors Endocrinology Field’s Leaders with 2026 Laureate Awards. September 10, 2025.
- U.S. Food and Drug Administration. FDA Approves First Treatment for Weight Management for People with Certain Rare Genetic Conditions. November 27, 2020.
